The U.S. Food and Drug Administration (FDA) has issued warnings to six companies marketing unapproved seizure treatments for pets, raising concerns about the safety and effectiveness of these products.
In a press release dated January 7, 2025, the FDA announced that warning letters had been sent to six firms distributing products that claim to treat seizures in dogs and cats. These companies include Nutrition Strength Ltd., Evolution Pets, Doc Ackerman’s Pet Products, Energetic Essences LLC, HD Frenchies LLC, and Vet Select Formula Inc.
The FDA emphasized that none of the products from these firms have been approved or conditionally approved for animal use.
Without FDA approval, there is no guarantee that these drugs are safe, effective, or produced under proper manufacturing standards. The FDA requires animal drugs to pass rigorous testing before they can be marketed.
The unauthorized products were found on company websites, social media platforms, and online retail stores like Amazon.
The FDA stated that drugs designed to control seizures in animals should only be administered under the supervision of a licensed veterinarian. Improper diagnosis or treatment can lead to severe health risks.
Seizures in animals, particularly idiopathic epilepsy, are common. Idiopathic epilepsy, which affects 1% to 5% of dogs, can be life-threatening.
The FDA has conditionally approved two drugs, KBroVet-CA1 and Fidoquel-CA1, to manage this condition. These drugs were authorized under a special approval pathway for critical conditions that lack sufficient treatment options.
The FDA urged pet owners currently using the flagged products to consult their veterinarians immediately. Discontinuing unapproved drugs and switching to proper veterinary care can protect pets from potential harm.
Additionally, the agency requested that consumers report adverse effects to the FDA’s Center for Veterinary Medicine.
The six companies have 15 days to respond to the FDA’s warning and outline their plans to address the violations. If no action is taken, the FDA may pursue legal measures, including product seizures or injunctions.
Key Points:
- The FDA warned six companies for selling unapproved seizure drugs for pets.
- Products lacked FDA approval, raising safety and effectiveness concerns.
- Pet owners were advised to consult veterinarians and discontinue use.
- FDA-approved seizure drugs for pets include KBroVet-CA1 and Fidoquel-CA1.
- Companies must respond to the FDA within 15 days or face legal action.